MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infection
Conditions
Complicated Intra-abdominal Infection
Trial Timeline
Jan 1, 2004 → Sep 1, 2004
NCT ID
NCT00157898About MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole is a approved stage product being developed by Merck for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00157898. Target conditions include Complicated Intra-abdominal Infection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00157898 | Approved | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infection